{'fraction_non_alphanumeric': 0.022922636103151862, 'fraction_numerical': 0.010506208213944603, 'mean_word_length': 5.429447852760736, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Research projects in Burkitt's lymphoma.

In July 1967, a collaborative research project, the Uganda Cancer Institute, was established at Makerere University, Kampala, with contract support from the National Cancer Institute. As a senior investigator from the NCI, I was sent to Uganda in an advisory capacity to help set up research projects in Burkitt's lymphoma and other cancers. Over the past five years more than 150 patients with Burkitt's lymphoma have been treated according to randomized clinical trials designed to improve the effectiveness of chemotherapy in this disease. These trials showed that 90% of patients with Burkitt's lymphoma had complete remissions following a single intravenous dose of cyclophosphamide, 40 mg/kg of body weight. Remissions were more durable in patients treated with multiple doses, as compared with a single dose, of the drug. Introduction of other agents in the primary treatment of the disease including vincristine sulfate, methotrexate, and cytosine arabinoside also improved remission duration, but